Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease. In a phase 2b dose-ranging study of baricit...

Descripción completa

Detalles Bibliográficos
Autores principales: Emery, Paul, Durez, Patrick, Hueber, Axel J., de la Torre, Inmaculada, Larsson, Esbjörn, Holzkämper, Thorsten, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784289/
https://www.ncbi.nlm.nih.gov/pubmed/33397481
http://dx.doi.org/10.1186/s13075-020-02379-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784289/
https://www.ncbi.nlm.nih.gov/pubmed/33397481
http://dx.doi.org/10.1186/s13075-020-02379-6

Ejemplares similares